WO2003011294A2 - Mucin synthesis inhibitors - Google Patents
Mucin synthesis inhibitors Download PDFInfo
- Publication number
- WO2003011294A2 WO2003011294A2 PCT/US2002/021315 US0221315W WO03011294A2 WO 2003011294 A2 WO2003011294 A2 WO 2003011294A2 US 0221315 W US0221315 W US 0221315W WO 03011294 A2 WO03011294 A2 WO 03011294A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- mucin
- compound
- talniflumate
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- This invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as asthma, chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases as well as chronic obstructive pulmonary diseases (COPD).
- diseases such as asthma, chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases as well as chronic obstructive pulmonary diseases (COPD).
- COPD chronic obstructive pulmonary diseases
- the airway epithelium is known to play an integral role in the airway defense mechanism via the mucociliary system and mechanical barriers. Recent studies indicate that airway epithelial cells (AEC) can be activated to produce and release biological mediators important in the pathogenesis of multiple airway disorders (Polito and Proud, 1998; Takizawa, 1998). Evidence has shown that the epithelium is fundamentally disordered in chronic airway disorders such as asthma, chronic bronchitis, emphysema, and cystic fibrosis (Holgate et al, 1999; Jeffery PK, 1991; Salvato, 1968; Glynn and Michaels, 1960). One of the hallmarks of these airway disorders is the over-production of mucus by AEC.
- mucus The major macromolecular components of mucus are the large glycoproteins known as mucins. Recently, the molecular structure of at least 7 human mucins was determined. The known mucin transcripts are heterogeneous with no sequence homology between the genes (Voynow and Rose, 1994), yet they are similar in their overall repetitive structure.
- Deleterious stimuli are known to activate AEC. These stimuli can vary from antigens in allergic disease to drugs or environmental pollutants, tobacco smoke, and infectious agents associated with forms of chronic obstructive pulmonary disease. AEC activation leads to altered ion transport, changes in ciliary beating, and the increased production and secretion of mucins leading to increased mucus.
- the mediators produced in response to AEC activation include chemokines that promote the influx of inflammatory cells (Takizawa, 1998). These inflammatory cells can in turn produce mediators that may injure AEC.
- AEC injury stimulates cellular proliferation (goblet cell and submucosal gland cell hyperplasia) that results in an expanded and continuous source of pro-inflammatory products, including proteases as well as growth factors that drive airway wall remodeling that can lead to lung destruction and the loss of function (Holgate et al, 1999).
- the over-production of mucus and alteration of its physiochemical characteristics can contribute to lung pathology in a number of ways. Disruption of physiologic mucociliary clearance by the over-production of mucins can lead to mucus plugging, air trapping, and atelectasis which is often complicated by infection.
- Asthma is a chronic obstructive lung disorder that appears to be increasing in prevalence and severity (Gergen and Weiss, 1992). It is estimated that 30-40% of the population suffers with atopic allergy and 15% of children and 5% of adults in the population suffer from asthma (Gergen and Weiss, 1992). In asthma, activation of the immune system by antigens leads to allergic inflammation. When this type of immune activation occurs it is accompanied by pulmonary inflammation, bronchial hyperresponsiveness, goblet cell and submucosal gland hyperplasia, and mucin over-production and hyper-secretion (Basle et al, 1989) (Paillasse, 1989) (Bosque et al, 1990).
- Mucus over-production and plugging associated with goblet cell and submucosal gland cell hyperplasia is an important part of the pathology of asthma and has been described on examination of the airways of both mild asthmatics and individuals who have died with status asthmaticus (Earle, 1953) (Cardell and Pearson, 1959) (Dunnill, 1960) (Dunnill et al, 1969) (Aikawa et al, 1992) (Cutz et al, 1978).
- Certain inflammatory cells are important in this reaction including T cells, antigen presenting cells, B cells that produce IgE, basophils that bind IgE, and eosinophils. These inflammatory cells accumulate at the site of allergic inflammation and the toxic products they release contribute to the destruction of AEC and other tissues related to these disorders.
- interleukin-9 interleukin-9
- mediator release from mast cells by allergen has long been considered a critical initiating event in allergy.
- IL9 was originally identified as a mast cell growth factor and it has been demonstrated that IL9 up-regulates the expression of mast cell proteases including MCP-1, MCP-2, MCP-4 (Eklund et al, 1993) and granzyme B (Louahed et al, 1995).
- IL9 appears to serve a role in the proliferation and differentiation of mast cells.
- IL9 up-regulates the expression of the alpha chain of the high affinity IgE receptor (Dugas et al, 1993). Furthermore, both in vitro and in vivo studies have shown IL9 to potentiate the release of IgE from primed B cells (Petit-Frere et ⁇ /., 1993).
- IL9 was shown to stimulate mucin synthesis and may account for as much as 50-60% of the mucin-stimulating activity of lung fluids in allergic airway disease (Longpre et al, 1999).
- a gross up-regulation of mucin synthesis and mucus over-production occurs in IL9 transgenic mice as compared to mice from the background strain.
- IL9 specifically up- regulates the MUC2 and MUC5 AC genes and proteins in vitro and in vivo (Louahed et al. , 2000).
- IL9 neutralizing antibody inhibits completely the up-regulation of mucins in response to antigen challenge in animal models of asthma (McLane et al, 2000).
- Current asthma treatments suffer from a number of disadvantages.
- beta-receptor agonists reduce the symptoms thereby transiently improving pulmonary function, but do not affect the underlying inflammation nor do they suppress mucin production.
- constant use of beta-receptor agonists results in desensitization, which reduces their efficacy and safety (Molinoff et al, 1995).
- the agents that can diminish the underlying inflammation, and thereby decrease mucin production, such as anti-inflammatory steroids, have their own list of disadvantages that range from immunosuppression to bone loss (Molinoff et al, 1995).
- Chronic bronchitis is another form of chronic obstructive pulmonary disorder. Nearly 5% of adults suffer with this pulmonary disorder.
- Chronic bronchitis is defined as the chronic over-production of sputum. Mucus over-production is generally associated with inflammation of the conducting airways. The mediators of inflammatory cells including neutrophils and macrophages may be associated with increased mucin gene expression in this disorder (Voynow et al, 1999; Borchers et al, 1999). The increased production of mucus is associated with airway obstruction, which is one of the cardinal features of this pulmonary disorder. Therapy is largely symptomatic and focused on controlling infection and preventing further loss of lung function. Decongestants, expectorants and combinations of these agents that are often used to treat the symptoms of bronchitis are not thought to alter mucin production.
- Mucolytics may promote mucociliary clearance and provide symptomatic relief by reducing the viscosity and/or the elasticity of the airway secretions but do not inhibit mucin synthesis or mucus over-production.
- Cystic fibrosis is yet another disease that effects the lung and is associated with thick secretions resulting in airway obstruction and subsequent colonization and infection by inhaled pathogenic microorganisms (Eng et al, 1996). DNA levels are increased significantly in CF lung and can increase the viscosity of sputum. While recombinant aerosolized DNAse is of value in these patients, there is no effective treatment for the pathologic mucus over-production. Thus, there is a specific unmet need in the art for the identification of agents capable of inhibiting mucin over-production by airway epithelial cells in CF.
- CF patients In addition to the airway obstruction caused by mucin secretions, CF patients also suffer from mucus plugging in the pancreatic ducts which prevent the delivery of digestive enzymes to the GI tract. The result is malabsorption syndrome, steatorrhea and diarrhea. Chronic non-allergic sinusitis is frequently accompanied by quantitative and qualitative changes in mucous production that contribute to the disease. These changes include hypersecretion of gel forming mucins such as MUC2, MUC5A/C and MUC5B. In addition, patients with chronic sinusitis frequently complain of mucoid or mucopurulent rhinorrhea. Recent research suggests that the hypersecretion involved in chronic sinusitis may be a result of locally increased mucin synthesis (Shinogi, et al., Laryngoscope 111(2):240-245, 2001).
- mucus over-production is one of the hallmarks of multiple chronic obstructive lung disorders
- the art lacks any methods to block the synthesis or over-production of mucins associated with these pulmonary disorders.
- the current invention relates to the discovery of agents that inhibit the synthesis and over-production of mucin glycoproteins and methods of using these molecules to treat the pathologic over-production of mucus in chronic obstructive pulmonary disorders and other diseases.
- the present invention provides a method of treating a subject with a respiratory disease characterized by the production of mucin, comprising administering to the subject an effective amount of a composition comprising at least one compound that decreases mucin synthesis or levels in the lungs or in the GI tract.
- the mucin synthesis may be chloride channel dependent.
- the compound decreases mucin synthesis in cells that express an ICACC chloride channel.
- the compound is selected from a group consisting of analogues and derivatives of anthranilic acid, analogues and derivatives of 2-amino-nicotinic acid, analogues and derivatives of 2-amino-phenylacetic acid, bendroflumethiazide, salts thereof and prodrugs thereof.
- the compound is selected from the group consisting of talniflumate, flufenamic acid, niflumic acid, mefenamic acid, salts thereof, derivatives thereof and prodrugs thereof.
- the compositions of the present invention comprise talniflumate, a talniflumate derivative, a salt thereof or a prodrug thereof.
- the compositions of the present invention may comprise at least one compound that decreases mucin synthesis or levels in the lungs or in the GI tract wherein the compound is a quinoline or quinoline derivative.
- the compound may be a quinoline modified with an amine group, preferably at the 2 or 3 position of the quinoline.
- the compound may be a 3-amino-quinoline in which the exocyclic nitrogen is modified with one or more moieties.
- the exocyclic amine group may be modified with an aromatic moiety.
- the aromatic moiety may be modified or unmodified.
- the aromatic group is a benzyl group which may be modified with one or more substituents. Suitable substituents include, but are not limited to, halogens.
- the compound is an N- (fluorobenzyl)-3-amino-quinoline ( Figure 19), preferably the fluorine is in the meta position.
- the compounds that decrease mucin synthesis are also inhibitors of the enzyme cyclooxygenase such as talniflumate.
- the compounds are specific inhibitors of the enzyme cyclooxygenase- 2.
- the present invention provides a method of treating a subject with a respiratory disease characterized by the production of mucin by administering the compositions of the invention by inhalation.
- the composition is in the form of a liquid or in the form of a powder.
- the composition is aerosolized.
- the composition further comprises at least one expectorant, antihistamine, mucolytic agent, antibiotic or decongestant agent.
- the expectorant is guaifenesin.
- the compositions of the invention may further comprise at least one stabilizing agent, absorption-enhancing agent or flavoring agent.
- the stabilizing agent is cyclodextran and/or the absorption- enhancing agent is chitosan.
- the compositions and methods of the present invention may be used to treat a respiratory disease selected from the group consisting of a chronic obstructive pulmonary disease (COPD), an inflammatory lung disease, cystic fibrosis and an acute or chronic infectious disease.
- COPD chronic obstructive pulmonary disease
- the treatment of any one of these diseases may be by administering one or more of the compositions of the invention via inhalation.
- the composition is administered via inhalation to the lungs.
- the present invention provides methods and materials to treat a COPD selected from the group consisting of emphysema, chronic bronchitis and asthma.
- compositions and methods of the present invention may be used to treat the GI complications of cystic fibrosis such as malabsorption syndrome, steatorrhea and diarrhea.
- the treatment of this disease may be by administering one or more of the compositions of the invention orally.
- the present invention provides a therapeutic composition formulated for inhalation delivery comprising an amount effective to decrease mucin production or levels of at least one compound selected from the group consisting of talniflumate, flufenamic acid, niflumic acid, mefenamic acid, salts thereof, derivates thereof and prodrugs thereof.
- the composition comprises talniflumate, a talniflumate derivative, a salt thereof or a prodrug thereof.
- the composition is in the form of a liquid or in the form of a powder.
- the composition further comprises at least one expectorant, mucolytic agent, antibiotic, anti-histamine or decongestant agent.
- the expectorant is guaifenesin.
- compositions of the present invention formulated for inhalation may further comprise at least one stabilizing agent, absorption-enhancing agent or flavoring agent.
- the stabilizing agent is a cyclodextran and/or the absorption-enhancing agent is chitosan.
- the present invention also provides an inhalation device comprising a therapeutic composition as described above.
- FIG 1 shows the effect of NFA on mucin production. NFA inhibitor blocks mucin overproduction in vitro.
- Figure 2 shows the ability of NFA and various compounds to suppress the overproduction of mucin by activated Caco2 cells. This figure shows the inhibition of mucin production in activated Caco2 cells by fenamates.
- FIG. 3 shows that treatment of the activated Caco2 cell line with NFA did not effect their viability. This figure shows that NFA does not effect epithelial cell proliferation.
- Figure 4 shows the inhibition of epithelial cell production of the chemokine eotaxin. This figure shows that NFA blocks epithelial activation including chemokine production.
- Figure 5 shows that intra-tracheal administration of NFA suppresses antigen-induced airway hyperresponsiveness (Af + NFA) compared to phosphate buffered saline (PBS). This figure shows that NFA blocks epithelial antigen responses including airway hyperresponsiveness.
- Figure 6 shows the results of intra-tracheal administration of NFA. This figure shows that NFA reduces antigen-induced lung eosinophilia in vivo. This is seen by comparing eosinophilia after activation with Aspergillus in the presence of NFA (Af + NFA) to eosinophilia after activation in the absence of NFA phosphate buffered saline (Af +PBS).
- Figure 7 shows the results of intra-tracheal administration of NFA on antigen-induced increases in mucus (mucin glyco-conjugates) (Af + NFA) compared to phosphate buffered saline (PBS). This figure shows NFA blocks increased mucin expression due to antigen in the lungs of exposed mouse.
- FIG 8 shows that IL9 transgenic mice constitutively over-produce mucin in the airway in contrast to control FVB mice.
- Figure 9 shows the constitutive over-production of mucin in the lung of IL9 transgenic mice is associated with the specific up-regulation of MUC2 and MUC5AC steady- state transcripts compared to the background strain (FVB/NJ) of mice. This figure shows that specific mucin genes are up-regulated in the lungs of IL-9 transgenic mice.
- Figure 10 shows the effect of anti-IL-9 antibody on mucin over-production in the lung of antigen-exposed mice. This figure shows neutralizing IL-9 antibody prevents mucin overproduction in antigen-exposed mice.
- Figure 11 shows a generic formula for phenyl anthranilic acid analogues that block mucin production
- X, to X 9 each independently of the others may be C, S, O or N
- R, to R ⁇ each independently of the others may be hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, halogen, halogen substituted alkyl, halogen substituted aryl, alkyl or aryl forming a ring, substituted alkyl or aryl forming a ring, hydroxyl, alkyl or aryl ether, amine, alkyl or aryl amine, alkyl or aryl ester, alkyl or aryl sulfonamide, thiol, alkyl or aryl thioether, alkyl or aryl sulfone, alkyl or aryl sulfoxide or sulfonamide
- Y carboxylate, alkyl carboxylate, sulfate, sulfonate, phosphate, phosphonate, amides of carboxylic
- Figure 12 shows mucin expression induced by hICACC-1 in NCI-H292 cells.
- Figure 13 shows mucus over-production in NCI-H292 cells over-expressing hlCACC- 1.
- Figure 14 shows the inhibition of mucin production by Talniflumate.
- Figures 15 A & B show the inhibition of mucin over production by oral administration if Talniflumate in mice.
- Figure 15A shows a section of lung (stained with H&E) from a mouse sensitized to Aspergillus fumigatus and allowed access to regular mouse chow.
- Figure 15B shows a section of lung (stained with H&E) from a mouse sensitized with Aspergillus fumigatus and allowed access to Talniflumate-containing mouse chow.
- Figure 16 shows the inhibition of lung eosinophilia by oral administration if Talniflumate in mice.
- This figure shows AHR373: the effect of Talniflumate mouse chow on BAL of B6D2F1/J male mice sensitized with Aspergillus fumigatus.
- Figure 17 shows the inhibition of MUC5A/C secretion by Nimesulide.
- Figure 18 shows the inhibition of MUC5A/C secretion by MSI-2079.
- Figure 19 shows the structure of MSI-2079.
- Figure 20 shows the effect of talniflumate on CF mice.
- Figure 21 shows the structures of MSI 2214-2217.
- Figure 22 shows the effect of talniflumate on the lipoteichoic acid dependent induction of MUC2.
- Figure 23 is a graph of chloride current as a function of voltage in cells expressing hICACC-1.
- the present invention is, in part, derived from the finding that mucus over-production resulting from activation of nonciliated epithelial cells of the lung is caused by induction of mucin genes including MUC2 and MUC5AC.
- one aspect of the invention is the inhibition of epithelial cell activation. This inhibition of AEC activation down-regulates chemokine production, bronchial responsiveness, and mucin gene expression. Molecules that decrease mucin synthesis or levels are therefore part of the invention.
- the formulations and compositions of the invention include agents that decrease mucin synthesis or levels, or decrease in some way the over-production of mucin.
- decrease is defined as a down-regulation in the level, activation, function, stability, or synthesis of mucin.
- Preferred agents decrease the chloride channel dependent level, activation, function, stability, or synthesis of mucin.
- chloride channel refers to, but is not limited to, the ICACC chloride channel and the related channels referred to in WO 99/44620, which is herein incorporated by reference in its entirety. Agents that fall under these definitions may be identified or their activity verified by screening in the assays described in the Examples. For instance, the in vitro and in vivo assays described in Examples 7 and 8 may be used to screen, identify or verify an agent's activity.
- Molecules that decrease mucin synthesis or levels include analogues and derivatives of anthranilic acid (2-aminobenzoic acid).
- the molecule may be an N-derivatized anthranilic acid.
- the amino group of anthranilic acid may be modified with one or more groups.
- the group may be an aromatic group.
- the group may be a trifluoromethyl- phenyl group preferably a 3-trifluoromethyl-phenyl group and the molecule that decreases mucin synthesis or levels is flufenamic acid.
- the amino group may be derivatized with a 2,3-dimethyl-phenyl group and the molecule that decreases mucin synthesis or levels is mefenamic acid.
- the benzoic acid ring may include one or more substituents.
- both the benzoic acid ring and the amino group may be modified.
- Other preferred embodiments include molecules having substituents on the benzoic acid ring and aromatic groups attached to the amino group.
- the molecules that decrease mucin synthesis include analogues and derivatives of 2-amino-nicotinic acid.
- the exocyclic amino group may be modified to include one or more groups.
- the exocyclic amine group may be modified with an aromatic group.
- Suitable aromatic groups include, but are not limited to, a phenyl group, a modified phenyl group, a benzyl group, a modified benzyl group and the like.
- the aromatic group may be a 3-trifluoromethyl-phenyl group and the derivative of 2-amino-nicotinic acid is niflumic acid.
- the molecule that decreases mucin synthesis may be an analogue or derivative of 2-amino-phenylacetic acid.
- the amino group may be modified to include one or more groups.
- the amino group may be modified with an aromatic group. Suitable aromatic groups include, but are not limited to, a phenyl group, a modified phenyl group, a benzyl group, a modified benzyl group and the like.
- the 2-amino-phenylacetic acid is N-modified with a 2, 6-dichlorophenyl group and the molecule that decreases mucin synthesis or levels is talniflumate.
- the molecule that decreases mucin synthesis or levels may be bendroflumethiazide.
- the present invention also contemplates the use of prodrugs of one or more of the above-mentioned molecules that decrease mucin synthesis or levels.
- a prodrug is a molecule that is administered in a form other than that described above and is converted in the body of the subject into the form described.
- Preferred prodrugs include, but are not limited to, prodrugs of fenamates.
- Some preferred prodrugs are esters of the acid form of the molecule that decreases mucin synthesis or levels.
- Preferred esters include, but are not limited to, esters of NFA, for example, the beta-morpholinoethyl ester, morniflumate, and the phthalidyl ester, talniflumate.
- agents that modulate, decrease or down-regulate the expression of mucin may be used to modulate biological and pathologic processes associated with mucin production.
- IL9 selectively induces the expression of mucin gene products.
- the pleiotropic role for IL9 which is important to a number of antigen- induced responses, is dependent in part, on the up-regulation of mucin in AEC.
- animals can be completely protected from antigen-induced responses in the lung. These responses include: bronchial hyperresponsiveness, eosinophilia and elevated cell counts in bronchial lavage, elevated serum IgE, histologic changes in lung associated with inflammation, and goblet cell and submucosal gland cell hyperplasia associated with the over-production of mucus.
- the untreated activated Caco2 cells stain intensely for PAS positive mucin glycoconjugates.
- Control and activated cells were cultured in the presence of niflumic acid (NFA) or 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS).
- NNFA niflumic acid
- DIDS 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid
- PAS staining of inhibitor treated activated cells revealed significantly fewer positive staining glycoconjugates as compared with the untreated cells ( Figure ID compared to IB).
- Mucin over production in cystic fibrosis is also present in the pancreatic ducts that deliver digestive enzymes to the GI tract resulting in malabsorption syndrome, steatorrhea and diarrhea. Applicants therefore also provide a method for treating cystic fibrosis by down regulating mucin production in the pancreas.
- Applicants have also identified a therapeutic potential for mucin down-regulation in chronic bronchitis and emphysema.
- Patients with chronic bronchitis and emphysema are hampered by lung disease characterized by thick secretions, which cause airway obstruction and subsequent colonization and infection by inhaled pathogenic microorganisms (Eng et al, 1996).
- Applicants therefore provide a method for treating chronic bronchitis and emphysema by down regulating mucin production in the lung.
- a subject can be any mammal, so long as the mammal is in need of modulation of a pathological or biological process mediated by mucin production.
- mammal is meant as an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects.
- Pathological processes refer to a category of biological processes that produce a deleterious effect.
- mucin over-production of the invention may be associated with respiratory disease, including chronic obstructive pulmonary disease (COPD), inflammatory lung disease, cystic fibrosis and an acute or chronic infectious disease.
- COPD chronic obstructive pulmonary disease
- inflammatory lung disease including, but is not limited to bronchitis, asthma and emphysema.
- Mucin over-production may also be associated with GI diseases such as malabsorption syndrome, steatorrhea and diarrhea that are present in cystic fibrosis.
- an agent is said to modulate a pathological process when the agent reduces the degree or severity of the process. For instance, airway obstruction may be prevented or disease progression modulated by the administration of agents that reduce or modulate in some way the synthesis, levels and or over-production of mucin.
- agents of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process.
- an agent of the present invention can be administered in combination with anti-asthma agents.
- an agent may be administered in combination with expectorants, mucolytics, antibiotics, antihistamines or decongestants.
- an agent may be administered along with a surfactant, a stabilizing agent, an absorption-enhancing agent, a beta adrenoreceptor or purine receptor agonist or a flavoring or other agent that increases the palatability of the compositions.
- compositions of the invention may contain, in addition to the active agent, an expectorant such as guaifenesin, a stabilizing agent such as cyclodextran and/or an absorption-enhancing agent such as chitosan. Any such agents may be used in the compositions of the invention.
- two or more agents are said to be administered in combination when the agents are administered simultaneously or are admimstered independently in a fashion such that the agents will act at the same time.
- the compounds used in the method of treatment of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered and similar considerations.
- the agents of the present invention can be administered via parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, topical, or buccal routes. Alternatively, or concurrently, administration may be by the oral or nasal route or directly to the lungs.
- the compounds of this invention may be administered by inhalation.
- the compound may be in a solution useful for administration by liquid aerosol, metered dose inhalers, or in a form suitable for a dry powder inhaler.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- the agents of the present invention may be formulated as aerosols.
- the formulation of pharmaceutical aerosols is routine to those skilled in the art, see for example, Sciarra, J. in Remington: The Science and Practice of Pharmacy 19 th Edition, Chapter 95, Mack Publishing Company, Easton, PA.
- the agents may be formulated as solution aerosols, dispersion or suspension aerosols of dry powders, emulsions or semisolid preparations.
- the aerosol may be delivered using any propellant system known to those skilled in the art.
- the aerosols may be applied to the upper respiratory tract, for example by nasal inhalation, or to the lower respiratory tract or to both.
- the therapeutic agents may be formulated into particulates or micronized to improve bioavailability and digestive absorption.
- talniflumate may be formulated and micronized using standard techniques in the art, including the methods discussed by Chaumeil,, J.C. et al., Methods Find. Exp. Clin. Pharmacol. 20(3):211-215 (1998).
- the grinding of talniflumate or other agents of the invention may be carried out in ball or hammer mills of the customary type. These procedures can also be carried out by micronization in gaseous jet micronizers which have the advantage of not heating the substances to be micronized.
- any common topical formulation such as a solution, suspension, gel, ointment or salve and the like may be employed. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's Pharmaceutical Sciences. For topical application, these compounds could also be administered as a powder or spray, particularly in aerosol form.
- the active ingredient may be administered in pharmaceutical compositions adapted for systemic administration. As is known, if a drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like or as a syrup or elixir for oral administration.
- the compound For intravenous, intra-peritoneal or intra-lesional administration, the compound will be prepared as a solution or suspension capable of being administered by injection. In certain cases, it may be useful to formulate these compounds in suppository form or as an extended release formulation for deposit under the skin or intra-muscular injection.
- compositions or agents contained therein are that amount that will reduce, decrease or down-regulate mucin activation, function, stability, or synthesis.
- Preferred compositions or agents reduce, decrease or down-regulate chloride channel dependent mucin activation, function, stability, or synthesis, including ICACC chloride channel dependent mucin activation, function, stability, or synthesis.
- a given effective amount will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment.
- a given effective amount will be best determined at the time and place through routine experimentation. It is anticipated, however, that in the treatment of chronic obstructive pulmonary disorders in accordance with the present invention, a formulation containing between 0.001 and 5 percent by weight, preferably about 0.01 to 1%, will usually constitute a therapeutically effective amount. When administered systemically, an amount between 0.01 and 100 mg per kg body weight per day, but preferably about 0.1 to 10 mg/kg/day, will effect a therapeutic result in most instances.
- a metered dose aerosol unit When administered via inhalation, an amount between 0.01 and 100 mg per kg body weight per day, but preferably about 0.10 to 10 mg/kg/day, will effect a therapeutic result in most instances.
- a metered dose aerosol unit contains about 0.8 mg of a compound of the present invention, for instance, talniflumate.
- the maintenance dose for an adult is about 2 inhalations (about 1.6 mg) twice daily (about 3.2 mg).
- the invention also includes pharmaceutical compositions comprising the compounds of the invention together with a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously or by inhalation.
- Saline or phosphate buffered saline can also be employed as carriers, particularly for inhalation by aerosols. Lactated saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, 1995.
- compositions of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically for delivery to the site of action.
- suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts.
- suspensions of the active compounds as appropriate oily injection suspensions may be administered.
- Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
- the suspension may also contain stabilizers as described above.
- Liposomes can also be used to encapsulate the agent for delivery into the cell.
- the pharmaceutical formulation for systemic administration according to the invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.
- Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and controlled release forms thereof.
- Suitable formulations for oral inhalation or nasal inhalation include aqueous solutions with or without excipients well known in the art.
- compositions or formulations of the invention may be packaged in containers, vials, inhalation devices, etc. with instructions or labels addressing the ability of the composition or formulation to promote lower respiratory tract drainage by thinning bronchial secretions, lubricating irritated respiratory tract membranes through increased mucous flow and/or facilitating the decreased production and removal of viscous, inspissated mucus.
- the label or instruction may also address indications and useage such as the maintenance of symptomatic relief of various conditions as herein described, including but not limited to, moderate to severe asthma, chronic bronchitis, cystic fibrosis, upper and lower respiratory tract infections and other conditions complicated by the persistence of viscous mucus in the respiratory tract or other places in the body.
- the devices of the present invention may be any device adapted to introduce one or more therapeutic compositions into the upper and/or lower respiratory tract.
- the devices of the present invention may be metered-dose inhalers.
- the devices may be adapted to deliver the therapeutic compositions of the invention in the form of a finely dispersed mist of liquid, foam or powder.
- the devices may use any propellant system known to those in the art including, but not limited to, pumps, liquefied- gas, compressed gas and the like.
- Devices of the present invention typically comprise a container with one or more valves throw which the flow of the therapeutic composition travels and an actuator for controlling the flow. Suitable devices for use in the present invention may be seen in, for example, in Remington: The Science and Practice of Pharmacy, 19 th Edition, Chapter 95, pages 1676-1692, Mack Publishing Co., Easton, PA 1995.
- Example 1 NFA inhibits mucin production by Caco2 cells activated to over-produce mucin
- Activated Caco2 cells that express the mRNA of MUCl, MUC2, MUC3, MUC4, MUC5B and MUC5AC have been produced and used to test for inhibitors of mucin production. These cells can be stained for mucin using Periodic Acid-Schiff staining (PAS).
- PAS Periodic Acid-Schiff staining
- FIG 1 shows that Caco2 control cells displayed a basal PAS staining with a few small glycoconjugates vesicles scattered about (panel A), activation of the Caco2 cells dramatically increased the number and intensity of PAS positive mucin glycoconjugates (panel B).
- the activated Caco2 cells were cultured in the presence of niflumic acid (NFA) or 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS).
- NFA niflumic acid
- DIDS 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid
- PAS staining of inhibitor treated activated Caco2 cells revealed significantly fewer positive staining mucin glycoconjugates as compared with the untreated cells ( Figure ID compared to IB).
- the slight staining seen in control cells was also inhibited (Figure IC compared to 1 A).
- Mucin production by activated Caco2 cells could also be inhibited by other fenamates such as Flufenamate (FFA), Tolfenamate (TFLA) and partially by Mefenamate (MFA) and Meclofenamate (MLFA) ( Figure 2).
- Related compounds Naproxen (MMNA) and Sulindac were ineffective. This reduced mucin production in NFA treated cells was not due to dramatic changes of the physiological condition of the cells, since their viability was not affected by even higher concentrations of NFA (Figure 3). Taken in total, the results are consistent with these drugs inhibiting epithelial activation.
- Example 2 NFA inhibits eotaxin production by Caco2 cells activated to over-produce mucin
- Activated LHL4 cells that express and secrete eotaxin have been produced and used to test for inhibitors of eotaxin production. These cells were assayed in vitro for eotaxin by an ELISA technique well known in the art (R&D Systems). As shown in Figure 4, activated LHL4 cells were cultured in the absence (control) or presence of increasing concentrations of niflumic acid (NFA). Significant inhibition of eotaxin production was noted with increasing concentrations of NFA. Similar inhibition was seen with DIDS and SIDS in an identical experiment. Mad/C3 cells show similar inhibition of eotaxin production by NFA, DIDS, and SIDS. Taken together, these results clearly demonstrate a direct effect of NFA on eotaxin production.
- Example 3 Inhibition of mucin overproduction in murine models of asthma by NFA Certified virus-free male and female mice of the following strains, DBA, C57B6 and B6D2F1 were purchased from the National Cancer Institute or Jackson Laboratories (Bar Harbor ME). IL-9 transgenic mice (Tg5) and their parent strain (FVB), were obtained from the Ludwig Institute (Brussels, Belgium). Animals were housed in a high-efficiency, particulate filtered air facility and allowed free access to food and water for 3 to 7 days prior to experimental manipulation. The animal facilities were maintained at 22°C and the light: dark cycle was automatically controlled (10:14 hour light: dark). Phenotyping and efficacy of pretreatment.
- mice either received no pretreatment or were sensitized by nasal aspiration of Aspergillus fumigatus antigen to assess the effect of pretreatment on bronchial hyperresponsiveness, composition of bronchoalveolar lavage fluid, mucin production and serum IgE.
- Mice were challenged with Aspergillus or saline intranasally (on days 0, 7, 14, 21 and 22) and phenotyped 24 hours after the last dose.
- Sensitized mice were treated on days 0- 21 with either PBS or 100 ⁇ g of NFA by intra-tracheal instillation (IT).
- IT intra-tracheal instillation
- Airway responsiveness is measured to one or more of the following: 5-hydroxytryptamine, acetylcholine, atracurium or a substance-P analog.
- APTI Airway Pressure Time Index
- IgE serum samples were measured using an ELISA antibody-sandwich assay.
- Microtiter plates were coated, 50 ⁇ l per well, with rat anti-murine IgE antibody (Southern Biotechnology) at a concentration of 2.5 ⁇ g/ml in a coating buffer of sodium carbonate- sodium bicarbonate with sodium azide. Plates were covered with plastic wrap and incubated at 4°C for 16 hours. The plates were washed three times with a wash buffer of 0.05% Tween- 20 in phosphate-buffered saline, incubating for five minutes for each wash.
- Blocking of nonspecific binding sites was accomplished by adding 200 ⁇ l per well 5% bovine serum albumin in phosphate-buffered saline, covering with plastic wrap and incubating for 2 hours at 37°C. After washing three times with wash buffer, duplicate 50 ⁇ l test samples were added to each well. Test samples were assayed after being diluted 1 :10, 1:50 and 1:100 with 5% bovine serum albumin in wash buffer. In addition to the test samples, a set of IgE standards (PharMingen) at concentrations from 0.8 ng/ml to 200 ng/ml in 5% bovine serum albumin in wash buffer, were assayed to generate a standard curve. A blank of no sample or standard was used to zero the plate reader (background).
- the plate was covered with plastic wrap and incubated for 2 hours at room temperature. After washing three times with wash buffer, 50 ⁇ l of secondary antibody rat anti-murine IgE- horseradish peroxidase conjugate was added at a concentration of 250 ng/ml in 5% bovine serum albumin in wash buffer. The plate was covered with plastic wrap and incubated 2 hours at room temperature. After washing three times with wash buffer, 100 ⁇ l of the substrate 0.5 mg/ml o-phenylenediamine in 0.1 M citrate buffer was added to every well. After 5-10 minutes the reaction was stopped with 50 ⁇ l of 12.5% sulfuric acid and absorbance was measured at 490 nm on a MR5000 plate reader (Dynatech). A standard curve was constructed from the standard IgE concentrations with antigen concentration on the x axis (log scale) and absorbance on the y axis (linear scale). The concentration of IgE in the samples was interpolated from the standard curve.
- Bronchoalveolar lavage (BAL) and cellular analysis were preformed as previously described (Kleeberger et al, 1990). Lung histology was carried out after either the lungs were filled with fixative in situ and place in formalin, or extracted and immediately frozen in liquid nitrogen. Since prior instrumentation may introduce artifact, separate animals were used for these studies. Thus, a small group of animals was treated in parallel exactly the same as the cohort undergoing various pre-treatments except these animals were not used for other tests aside from bronchial responsiveness testing. After bronchial responsiveness testing, lungs were removed and submersed in liquid nitrogen as above. Cryosectioning, staining, and histologic examination was carried out in a manner obvious to those skilled in the art.
- NFA which blocks epithelial cell activation and down-regulates mucin and eotaxin production in vitro, was used therapeutically to assess the importance of epithelial cell activation in vivo on antigen-induced mucin production, bronchial responsiveness, serum IgE, and airway inflammation as assessed by BAL in mice.
- the effects of NFA treatment, on airway responsiveness, BAL, mucus production, and serum IgE levels relative to vehicle treated matched controls were determined.
- Figures 5 and 6 show that NFA is able to suppress airway hyperresponsiveness and BAL lung eosinophilia respectively, however, there was no effect on serum IgE levels.
- NFA could also suppress the over-production of mucus in the lung caused by exposure to antigen (Figure 7).
- Example 4 Epithelial activation by IL9 in a transgenic mouse produces mucus overproduction and mucin gene up-regulation. A model for drug screening.
- IL9TG5-FVB/N mice Certified virus-free male and female IL9 transgenic mice (IL9TG5-FVB/N) 5-6 weeks of age were bred in our laboratories. Male and female FVB/N mice 5-6 weeks of age were purchased from Jackson Laboratories (Bar Harbor ME). Animals were housed in high- efficiency, particulate filtered air and allowed free access to food and water for 3 to 7 days prior to experimental manipulation. The animal facilities were maintained at 22°C and the light:dark cycle was automatically controlled (10:14 hour lightidark). Phenotyping and efficacy of treatment.
- mice Animals were phenotyped, na ⁇ ve, or 24 hrs after receiving intra-tracheal (IT) shame (vehicle) treatment, or drugs in the same vehicle as was used in identically treated controls. Mice were treated IT once daily for three days. NFA (100 ⁇ g) or antibody to IL-9 were administered in PBS IT. Treatment responses were measured by the assessment of mucin inhibition by histologic exam (PAS staining of greater than 10 sections through the treated and control lungs or western blots of MUCl, MUC2 and MUC3 expression from the same lungs. Figure 8 shows that IL-9 transgenic mice constitutively overproduce mucin as compared to control FVB mice.
- Example 5 Inhibition of mucin over production in murine models of asthma by Talniflumate. Certified virus-free male B6D2F1 mice 5-6 weeks of age were purchased from
- Talniflumate containing mouse chow or regular mouse chow Animals either received no sensitization or were sensitized by nasal aspiration of Aspergillus fumigatus antigen to assess the effect of pretreatment on bronchial hyperresponsiveness, composition of bronchoalveolar lavage fluid, mucin production and serum IgE. Mice were challenged with Aspergillus intranasally (on days 0, 7, 16 and 17) and phenotyped 24 hours after the last dose. The inhibition of mucus production in the lung was used to assess the treatment effect of Talniflumate, or could be used to assess the treatment effects of other drug candidates.
- Airway responsiveness is measured to one or more of the following: 5-hydroxytryptamine, acetylcholine, atracurium or a substance-P analog.
- APTI Airway Pressure Time Index
- Treatment responses were measured by the assessment of mucin inhibition by histologic exam (PAS staining of the treated and control lungs). Oral treatment with Talniflumate reduced mucin staining.
- Figure 15 A shows the PAS staining in mouse lung obtained from Asp-sens mice that were fed regular mouse chow.
- Figure 15B shows the results obtained from Asp-sens mice fed Talniflumate containing chow.
- Figure 16 shows the results of feeding talniflumate coated mouse chow on lung eosinophilia determined by bronchoalveolar lavage. Talniflumate reduced the number of eosinophilic cells obtained from mice sensitized to Aspergillus fumigatus as compared to sensitized mice fed standard mouse chow.
- NCI-H292 cells a human pulmonary mucoepidermoid carcinoma cell line, were purchased from the American Type Culture Collection (Manassas VA) and cultured in RPMI1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin (Gibco/BRL). The cells were grown in a humidified, air-containing incubator, supplemented with 5% CO 2 at 37°C. Stable NCI-H292 cell lines over-expressing hICACC-1 were established by transfection of pcDNA3-hICACC-l using a Fujin Transfection kit according to the manufacture's instruction (Boehringer-Mannheim).
- a control cell line was produced, NCI-H292/ctl, by the transfection of pcDNA3 (ctl) into the NCI-H292 cell line using the same procedure. Expression of the hICACC-1 gene was confirmed for the pcDNA3- hICACC-1 transfectent by Northern analysis.
- s-ELLA specific enzyme linked lectin assay
- cells were plated in 24-well tissue culture plates and incubated for 72 hours to confluence. Supernatants were transferred into 96-well plates pre-coated with 1 ⁇ g/ml anti-MUC5A C antibody (New marker, Fremont CA) and blocked with 1 % BSA. Antibody bound MUC5 A/C was then detected with HRP-lectin (Sigma).
- RNA was isolated from cell lines using Trizol reagent (Gibco/BRL) following the manufacturer's protocol.
- RT-PCR was performed by reverse transcribing 1 ⁇ g of total RNA and amplifying cDNA with the appropriate primers by PCR. Products were separated by electrophoreses on 2% agarose gels and visualized by ethidium bromide staining. Primer pairs used to generate human ICACC-1 message were: sense 5'- GGCACAGATCTTTTCATTGCTA-3' and antisense 5'-
- NCI-H292 cells express MUCl constitutively, whereas MUC2 and MUC5A/C mRNA expression are below detection levels at baseline.
- Figure 12A shows the results of a Northern blot analysis of pcDNA3-hICACC-l transfected cells showing an increased expression level for ICACC mRNA.
- Western blot analysis of whole cell lysate from ICACC-1 over- expressing clones revealed enhanced MUC2 protein production (Figure 12B).
- MUC5A C expression was significantly increased in ICACC-1 over-expressing cells, while MUCl was unchanged in RT-PCR analyses ( Figure 12C).
- Specific ELLA analysis also revealed the over-production of MUC5A/C protein in ICACC-1 expressing clones compared with the untransfected NCI-H292 cells or cells transfected with empty vector ( Figure 12D).
- Example 7 Inhibition of Mucus over-production and MUC 5 A/C expression in NCT H292 cells over-expressing hICACC-1
- NCI-H292/ctl and NCI- H292/hICACC-l were cultured in 24-well plates for 3 days. Cells were then fixed with Formalin and mucous glycoconjugates were visualized by AB/PAS staining (Sigma). Although NCI-H292 control cells displayed a basal PAS staining with a few scattered granules ( Figure 13 A), over-expression of ICACC-1 dramatically increased the number and intensity of PAS positive muco-glycoconjugates ( Figure 13B).
- NFA niflumic acid
- MFA mefanamic acid
- PAS staining of cells treated with NFA, MFA or talniflumate revealed significantly fewer positive staining muco-glycoconjugates compared with untreated cells ( Figures 13C & D and insert of Figure 14). PAS staining of inhibitor treated control cells showed virtually no difference from untreated cells ( Figures 13A & C).
- the IC 50 values for Talniflumate ( Figure 14), Nimesulide (Figure 17) and MSI-2079 (Figure 18, the structure of MSI-2079 is shown in Figure 19) were determined on the basis of its inhibition of MUC5A C secretion in hCLCAl expressing H292 cells. Confluent cells were treated with the inhibitor at concentrations from 0 through 250 ⁇ M in OPTI MEM. Secreted MUC5A C was detected forty-eight hours after addition of the inhibitor by an ELLA assay as described in Example 5. The IC50 values were determined with the data analyzing software GraphPad Prism. The insert of Figure 14 shows the intracellular mucin levels in response to Talniflumate treatment detected by PAS staining.
- Example 8 Effects of Talniflumate and Analogs in CF Assays CF mice (both CF knock-out mice and CF ⁇ F508 mice), which do not express a functioning CFTR protein, were weaned and administered an osmotic agent to allow survival. Within two weeks of weaning, the osmotic agent treatment was discontinued and the mice were either placed on talniflumate containing chow or control chow. The CF mice consuming control chow lost 10-15% body weight and died (CF knock-out) or were euthanized (CF ⁇ F508) due to the animal's moribund state within 7 days post-osmotic agent. In contrast, the CF mice that consumed talniflumate (approximate dose of 100 mg/kg per os) gained 8-12% body weight and survived at least 26 days, at which time they were sacrificed to evaluate histopathology (see Figure 20).
- the desired analogues of talniflumate were synthesized via the reaction scheme depicted below.
- the anion of dimethyl methylphosphonate was generated by adding butyl lithium to the phosphonate at -78°C in tetrahydrofuran.
- Niflumic acid methyl ester (1 [see corresponding compound numbers in Table 2]) was added to this solution of phosphonate carbanion to generate the ⁇ -keto phosphonate (2).
- the phosphonate carbanion of (2) is generated by the addition of base, sodium tertbutoxide, to a solution of (2) in tetrahydrofuran.
- Example 9 Effects of Talniflumate in a COPD Assay MUC2 transcription was monitored as described in Li et al. (1998) Proc. Natl Acad. Sci., USA, Vol. 95, pp. 5718-5723. Briefly, an epithelial cell line was transfected with a reporter construct containing the promoter region from the MUC2 gene cloned upstream of a luciferase reporter gene. Transfected cells were treated with serum free media (SFM) alone or, as indicated, containing hpoteichoic acid from S. aureus bacteria (LTA), adenosine (aden), or talniflumate (MSI).
- SFM serum free media
- LTA S. aureus bacteria
- aden adenosine
- MSI talniflumate
- Example 10 Effects of Talniflumate on Chloride Channel Activity
- Figure 23 shows the results of a patch clamp experiment on cells transfected with a plasmid expressing a chloride channel.
- An NCI-H292 cell transfected with a plasmid expressing the human chloride channel hICACC-1 was patch clamped and chloride current (I) was measured over a range of voltages (V).
- Substantial chloride current was invoked by the addition of 2 ⁇ M ionomycin and 2 mM calcium (circles) compared to baseline (squares), indicating activation of hICACC-1.
- Addition of 5 micromolar talniflumate (triangles) produced a reduction in chloride current at positive voltage, indicating an inhibition of channel activity.
- diclofenac did not inhibit chloride channel activity.
- a HEK293 cell transfected with a plasmid expressing a murine chloride channel, mICACC-1 was patch clamped and chloride current was measured over a range of voltages (V, left column) and the results are shown in Table 3 below. Each row lists currents invoked at a particular positive voltage in the absence (-) or presence (+) of ionomycin and calcium, and in the presence of an indicated concentration of diclofenac ( ⁇ M).
- Substantial current was invoked by the addition of 2 ⁇ M ionomycin and 2 mM calcium- compare the first two columns-indicating activation of mICACC-1 by the ionomycin/calcium treatment.
- the chloride current was increased from 39 nA/pF to 105 nA/pF.
- concentrations of diclofenac ranging from 5 ⁇ M to 50 ⁇ M.
- Glycophorin A interacts with interleukin-2 and inhibits interleukin-2-dependent T-lymphocyte proliferation. Cell. Immunol. 145, 223-239, 1992.
- Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur. J. Immunol. 23, 1687-1692, 1993.
- Dunnill MS The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Invest, 13, 27-33, 1960.
- Gergen PJ The association of allergen skin test reactivity and respiratory disease among whites in the U.S. population. Arch. Intern. Med. 151. 487-492, 1991.
- Halonen M Stem D, Taussig LM, Wright A, Ray CG and Martinez FD.
- Kleeberger SR, Bassett DJ, Jakab GJ and Levitt RC A genetic model for evaluation of susceptibility to ozone-induced inflammation. Am. J. Physiol. 258, L313-320, 1990.
- Levitt RC and Ewart SL Genetic susceptibility to atracurium-induced bronchoconstriction. Am. J. Respir. Crit. Care. Med. 151, 1537-1542, 1995. Levitt RC. Understanding biological variability in susceptibility to respiratory disease. Pharmacogenetics 1, 94-97, 1991.
- McLane MP Tepper J, Weiss C, Tomer Y, Taylor RE, Tumas D, Zhou Y, Haczku A, Nicolaides NC and Levitt, RC.
- Lung delivery of an Interleukin-9 antibody treatment inhibits airway hyper-responsiveness (AHR), BAL eosinophilia, mucin production and serum IgE elevation to natural antigens in a murine model of asthma.
- AHR airway hyper-responsiveness
- BAL eosinophilia BAL eosinophilia
- mucin production mucin production
- serum IgE elevation to natural antigens in a murine model of asthma.
- AAAAI 3/3- 3/8/2000 in San Diego, CA and for ATS/ALA meeting: 5/5/2000 in Toronto, Canada.
- Interleukin-9 potentiates the interleukin-4-induced IgE and IgGl release from murine B lymphocytes. Immunology 79, 146-151, 1993.
- Salvato G Some histologic changes in chronic bronchitis and asthma. Thorax, 23, 168-72, 1968. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ and Holdaway MD.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02749809A EP1418914A2 (en) | 2001-08-02 | 2002-08-02 | Mucin synthesis inhibitors |
CA002455975A CA2455975A1 (en) | 2001-08-02 | 2002-08-02 | Mucin synthesis inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/920,287 | 2001-08-02 | ||
US09/920,287 US20020165244A1 (en) | 2000-01-31 | 2001-08-02 | Mucin synthesis inhibitors |
US09/951,906 US20020147216A1 (en) | 2000-01-31 | 2001-09-14 | Mucin synthesis inhibitors |
US09/951,906 | 2001-09-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003011294A2 true WO2003011294A2 (en) | 2003-02-13 |
WO2003011294A3 WO2003011294A3 (en) | 2004-03-11 |
Family
ID=27129796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/021315 WO2003011294A2 (en) | 2001-08-02 | 2002-08-02 | Mucin synthesis inhibitors |
Country Status (4)
Country | Link |
---|---|
US (1) | US20020147216A1 (en) |
EP (1) | EP1418914A2 (en) |
CA (1) | CA2455975A1 (en) |
WO (1) | WO2003011294A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100166726A1 (en) * | 2007-03-07 | 2010-07-01 | Northeastern University | Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2757510B1 (en) * | 1996-12-23 | 2000-01-07 | Sanofi Sa | MICROPARTICLE FORM OF A TETRAHYDROPYRIDINE DERIVATIVE |
US7345051B2 (en) * | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
ITMI20050417A1 (en) | 2005-03-15 | 2006-09-16 | Medestea Res & Production S R L | USE OF NON-STEROID ANTI-INFLAMMATORY DRUGS BY INHALATION IN THE THERAPY OF ACUTE AND CHRONIC BRONCHITIS |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4515980A (en) * | 1983-07-11 | 1985-05-07 | Sterling Drug Inc. | Substituted aminobenzoates, their preparation and use |
US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
EP0174006A2 (en) * | 1984-09-04 | 1986-03-12 | Richardson-Vicks, Inc. | Antidiarrheal compositions and use thereof |
WO1997003659A1 (en) * | 1995-07-20 | 1997-02-06 | Uwe Juergens | Use of a non-steroidal anti-inflammatory drug for topical and systemic treatment of acute and chronic polypoid rhinosinusitis |
WO1997003678A1 (en) * | 1995-07-15 | 1997-02-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts |
WO1998042708A2 (en) * | 1997-01-08 | 1998-10-01 | Pharmacia & Upjohn Company | Pharmaceutically active tricyclic amines |
US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
EP0935964A1 (en) * | 1998-02-12 | 1999-08-18 | Panacea Biotec Limited | Pharmaceutical compositions containing NSAIDs and piperine |
WO2001022935A1 (en) * | 1999-09-27 | 2001-04-05 | Oh Jun Suk | Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same |
WO2001054685A1 (en) * | 2000-01-31 | 2001-08-02 | Genaera Corporation | Mucin synthesis inhibitors |
WO2001085146A1 (en) * | 2000-05-12 | 2001-11-15 | Astrazeneca Ab | Pharmaceutical compounds for treating copd |
-
2001
- 2001-09-14 US US09/951,906 patent/US20020147216A1/en not_active Abandoned
-
2002
- 2002-08-02 WO PCT/US2002/021315 patent/WO2003011294A2/en not_active Application Discontinuation
- 2002-08-02 CA CA002455975A patent/CA2455975A1/en not_active Abandoned
- 2002-08-02 EP EP02749809A patent/EP1418914A2/en not_active Withdrawn
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4515980A (en) * | 1983-07-11 | 1985-05-07 | Sterling Drug Inc. | Substituted aminobenzoates, their preparation and use |
US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
US4552899B1 (en) * | 1984-04-09 | 1992-10-20 | Analgesic Associates | |
EP0174006A2 (en) * | 1984-09-04 | 1986-03-12 | Richardson-Vicks, Inc. | Antidiarrheal compositions and use thereof |
WO1997003678A1 (en) * | 1995-07-15 | 1997-02-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts |
WO1997003659A1 (en) * | 1995-07-20 | 1997-02-06 | Uwe Juergens | Use of a non-steroidal anti-inflammatory drug for topical and systemic treatment of acute and chronic polypoid rhinosinusitis |
US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
WO1998042708A2 (en) * | 1997-01-08 | 1998-10-01 | Pharmacia & Upjohn Company | Pharmaceutically active tricyclic amines |
EP0935964A1 (en) * | 1998-02-12 | 1999-08-18 | Panacea Biotec Limited | Pharmaceutical compositions containing NSAIDs and piperine |
WO2001022935A1 (en) * | 1999-09-27 | 2001-04-05 | Oh Jun Suk | Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same |
WO2001054685A1 (en) * | 2000-01-31 | 2001-08-02 | Genaera Corporation | Mucin synthesis inhibitors |
WO2001085146A1 (en) * | 2000-05-12 | 2001-11-15 | Astrazeneca Ab | Pharmaceutical compounds for treating copd |
Non-Patent Citations (11)
Title |
---|
BOBIN S ET AL: "A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF NIFLUMIC ACID IN THE TREATMENT OF ACUTE SINUSITIS" CURRENT THERAPEUTIC RESEARCH CLINICAL AND EXPERIMENTAL, vol. 46, no. 6, 1989, pages 1119-1128, XP008020212 ISSN: 0011-393X * |
CHAO A C ET AL: "Niflumic and flufenamic acids are potent inhibitors of chloride secretion in mammalian airway." LIFE SCIENCES. ENGLAND 1992, vol. 51, no. 18, 1992, pages 1453-1457, XP008020257 ISSN: 0024-3205 * |
CUTHBERT, ALAN W.: "Assessment of CFTR chloride channel openers in intact normal and cystic fibrosis murine epithelia" BRITISH JOURNAL OF PHARMACOLOGY ( 2001 ), 132(3), 659-668, XP002249627 * |
GABRIEL S E ET AL: "Permeabilization via the P2X7 purinoreceptor reveals the presence of a Ca2+-activated Cl- conductance in the apical membrane of murine tracheal epithelial cells." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 10 NOV 2000, vol. 275, no. 45, 10 November 2000 (2000-11-10), pages 35028-35033, XP002249625 ISSN: 0021-9258 * |
JACKSON R H ET AL: "New therapy in bronchial asthma. An evaluation of ponstel (mefenamic acid) in chronic bronchial asthma and pulmonary emphysema." THE JOURNAL OF THE KANSAS MEDICAL SOCIETY. UNITED STATES OCT 1968, vol. 69, no. 10, October 1968 (1968-10), pages 474-478, XP008020211 ISSN: 0022-8699 * |
MCCARTY, N. A. ET AL: "Voltage-dependent block of the cystic fibrosis transmembrane conductance regulator chloride channel by two closely related arylaminobenzoates" JOURNAL OF GENERAL PHYSIOLOGY ( 1993 ), 102(1), 1-23, XP002249628 * |
MELICA A ET AL: "A new anti-inflammatory, analgesic, antipyretic drug, morniflumate, for chronic relapsing bronchitis" EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 1991 ITALY, vol. 13, no. 1-2, 1991, pages 51-60, XP008020214 ISSN: 0392-291X * |
MOCHIZUKI H ET AL: "The effect of non-steroidal anti-inflammatory drugs on the electrical properties of cultured dog tracheal epithelial cells." EUROPEAN JOURNAL OF PHARMACOLOGY. NETHERLANDS 3 FEB 1994, vol. 252, no. 2, 3 February 1994 (1994-02-03), pages 183-188, XP008020256 ISSN: 0014-2999 * |
WAGNER J A ET AL: "MOLECULAR STRATEGIES FOR THERAPY OF CYSTIC FIBROSIS" ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, ANNUAL REVIEW INC., PALO ALTO, CA, US, vol. 35, no. 35, 1995, pages 257-276, XP000905581 ISSN: 0362-1642 * |
WIDDICOMBE J H ET AL: "Regulation of airway mucosal ion transport." INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY. SWITZERLAND 1991, vol. 94, no. 1-4, 1991, pages 56-61, XP008020298 ISSN: 0020-5915 * |
WINPENNY J P ET AL: "Calcium-activated chloride conductance in a pancreatic adenocarcinoma cell line of ductal origin (HPAF) and in freshly isolated human pancreatic duct cells." PFLUGERS ARCHIV: EUROPEAN JOURNAL OF PHYSIOLOGY. GERMANY MAY 1998, vol. 435, no. 6, May 1998 (1998-05), pages 796-803, XP002249626 ISSN: 0031-6768 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100166726A1 (en) * | 2007-03-07 | 2010-07-01 | Northeastern University | Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation |
Also Published As
Publication number | Publication date |
---|---|
EP1418914A2 (en) | 2004-05-19 |
US20020147216A1 (en) | 2002-10-10 |
WO2003011294A3 (en) | 2004-03-11 |
CA2455975A1 (en) | 2003-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7504409B2 (en) | Mucin synthesis inhibitors | |
AU2001234671A1 (en) | Mucin synthesis inhibitors | |
US7345051B2 (en) | Mucin synthesis inhibitors | |
Lara-Reyna et al. | Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations | |
Zhu et al. | PM2. 5 induces autophagy-mediated cell death via NOS2 signaling in human bronchial epithelium cells | |
Yoo et al. | Antioxidant polymeric nanoparticles as novel therapeutics for airway inflammatory diseases | |
US20020165244A1 (en) | Mucin synthesis inhibitors | |
US20050249675A1 (en) | Mucin synthesis inhibitors | |
CN110769824A (en) | IL-8 inhibitors for the treatment and/or prevention of bacterial secondary infections | |
Ong et al. | The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia | |
Bao et al. | Impact of ozone exposure on the response to glucocorticoid in a mouse model of asthma: involvements of p38 MAPK and MKP-1 | |
US20020147216A1 (en) | Mucin synthesis inhibitors | |
Çetinel et al. | Leukotriene D4 receptor antagonist montelukast alleviates protamine sulphate‐induced changes in rat urinary bladder | |
AU2002320299A1 (en) | Mucin synthesis inhibitors | |
JP2002338493A (en) | Mucin synthesis inhibitor | |
JP2002338494A (en) | Mucin synthesis inhibitor | |
Davies | New therapeutic approaches for cystic fibrosis lung disease. | |
Zhang et al. | A large particle size is required by a nano/micron sized-fluticasone propionate inhalable suspension for asthma treatment | |
JP2019505538A (en) | Compositions and methods for the treatment of sinus diseases and disorders | |
Utembe et al. | Immunotoxicity of engineered nanomaterials and their role in asthma | |
Tadros | RETRACTED ARTICLE: The Influence of Sodium Hyaluronate, l-Leucine and Sodium Taurocholate on the Nebulization of Aqueous Betamethasone-17-Valerate Suspensions | |
Hagner | Relationship between impaired mucociliary clearance and airway inflammation in chronic airway diseases | |
Vartiainen | INHALABLE ANTIFIBROTIC COMPOUNDS | |
J Ragavan | Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2455975 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002320299 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002749809 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002749809 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002749809 Country of ref document: EP |